Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M

Kiniksa Pharmaceuticals International, plc

2025-Q3 EPS reported $0.57 revenue$475,437,000

Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.
ARCALYST net product revenue $180.9M, up 61% YoY; total revenue $180.9M.
2025 revenue guidance raised to $670-675M from prior $625-640M.
KPL-387 granted Orphan Drug Designation; Phase 2/3 data H2 2026.
Prescribers >3,825; average therapy duration ~32 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.